Momenta Must Face Clot Drug Antitrust Row, 1st Circ. Told
Misconduct by Momenta before a standard-setting organization that unknowingly led the group to create a standard for a blood-clot drug that requires the use of a company patent should not allow...To view the full article, register now.
Already a subscriber? Click here to view full article